Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : YMI: YM Biosciences, Inc. (YMI on AMEX) -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (32)	3/10/2007 1:44:18 PM
From: LaFayette555	Respond to of 66

glad you agree with me ! it is time to buy indeed !

To: DewDiligence_on_SI who wrote (32)	4/3/2007 10:35:42 AM
From: LaFayette555	Respond to of 66

It's easy as 1 2 3 : Buy Low Sell High ! It's called value investing. Got nothing to do with HEAVY in depth analysis of the fundamentals, after all how can one bank on any analysis with a degree of certaincy when the outcome is a random binary event. To do so would indicates a basic misunderstanding of reality as it is. BTW with any 'luck' we have not seen the highs by far yet.

To: DewDiligence_on_SI who wrote (32)	5/2/2007 9:38:00 PM
From: LaFayette555	Read Replies (1) \| Respond to of 66

Versant analyst Douglas Loe upgraded his recommendation on YM Biosciences Inc. (AMEX: YMI - News) Tuesday, following a recent trip to Cuba, where YM's head and neck cancer treatment, the nimotuzumab antibody, is being developed. In a note to clients, Mr. Loe said he remains positive following visits to the Center of Generic Engineering and Biotechnology and the Center for Molecular Immunology in Havana, that nimotuzumab's potential to confer 'efficacy without rash' remains a key point of differentiation from other comparable cancer drugs such as Erbitux and Vectibix. Although he said larger combination-therapy trials are still required, Mr. Loe increased his rating on YM shares from 'hold' to 'speculative buy' and raised his price target from C$2.50 to C$4.25. The introduction of revenue projections for nimotuzumab sales in Japan by YM’s partner, Daiichi Pharmaceutical Co., also contributed to the upgrade, he added. YM, who licenses nimotuzumab in Europe, North America, Japan and the Pacific Rim countries, excluding China, received approval last September to import nimotuzumab into the U.S. for clinical trials in pediatric patients with pontine glioma, an inoperable malignant brain cancer